Authors
Writing Committee Members, Steve R Ommen, Carolyn Y Ho, Irfan M Asif, Seshadri Balaji, Michael A Burke, Sharlene M Day, Joseph A Dearani, Kelly C Epps, Lauren Evanovich, Victor A Ferrari, José A Joglar, Sadiya S Khan, Jeffrey J Kim, Michelle M Kittleson, Chayakrit Krittanawong, Matthew W Martinez, Seema Mital, Srihari S Naidu, Sara Saberi, Christopher Semsarian, Sabrina Times, Cynthia Burstein Waldman
Published in
Journal of the American College of Cardiology. May 03, 2024. Epub May 03, 2024.
Abstract
The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.
A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.
Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy" have been updated with new evidence to guide clinicians.
PMID:
38727647
Bibliographic data and abstract were imported from PubMed on 10 May 2024.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 49
- Comments 0